aTyr Pharma to Present at November Investor Conferences

Rhea-AI Summary

aTyr Pharma, Inc. (Nasdaq: LIFE) will present at two investor conferences in November 2023. The first is the Jefferies London Healthcare Conference on November 15 in London, UK, and the second is the Piper Sandler 35th Annual Healthcare Conference on November 30 in New York, NY. The company's management will also be available for one-on-one meetings with investors. Webcasts of each event will be available on the company's website, and replays will be accessible for at least 90 days.

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences scheduled to take place in November 2023.

Details of the presentations appear below:

Conference: Jefferies London Healthcare Conference
Date: Wednesday, November 15, 2023
Time: 3:30pm GMT
Location: London, UK
Format: Corporate Presentation

Conference: Piper Sandler 35^th Annual Healthcare Conference
Date: Thursday, November 30, 2023
Time: 12:00pm EST
Location: New York, NY
Format: Fireside Chat

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of each event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com

FAQ

When and where will aTyr Pharma be presenting at investor conferences in November 2023?

aTyr Pharma will be presenting at the Jefferies London Healthcare Conference on November 15 in London, UK, and at the Piper Sandler 35th Annual Healthcare Conference on November 30 in New York, NY.

Will aTyr Pharma's management be available for meetings with investors?

Yes, aTyr Pharma's management will be available for one-on-one meetings with investors who are registered attendees of the conferences.

Where can I find webcasts of the presentations?

Webcasts of the presentations will be available on the Investor's section of aTyr Pharma's website at www.atyrpharma.com.

How long will the replays of the presentations be available?

Replays of the presentations will be available on aTyr Pharma's website for at least 90 days.

What is aTyr Pharma's lead therapeutic candidate?

aTyr Pharma's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease.

What is interstitial lung disease?

Interstitial lung disease is a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs.

What is aTyr Pharma's focus in drug discovery?

aTyr Pharma leverages evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

What is aTyr Pharma's discovery platform based on?

aTyr Pharma's discovery platform is based on uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases.